Study of a drug combo for lung cancer that spread to the spinal fluid
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (pemetrexed given into the spinal fluid, high-dose furmonertinib by mouth, and bevacizumab) for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastases). The goal is to see if this treatment can help control the cancer in this hard-to-treat area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have non-small cell lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastases).
- Your cancer must have a specific EGFR mutation and have gotten worse after treatment with a third-generation EGFR targeted therapy.
- You must be able to care for yourself (ECOG score 0-2) and have an expected survival of at least 12 weeks.
- You must have adequate bone marrow and organ function (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called intrathecal pemetrexed, which is chemotherapy given directly into the fluid around your brain and spine. It's for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord after targeted therapy stopped working.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests a higher dose of the targeted pill firmonertinib combined with two other drugs (bevacizumab and pemetrexed) given into the spine for people with EGFR-mutant lung cancer that has spread to the lining of the brain. It aims to see if this combination can shrink or control the cancer in the central nervous system.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This study tests a drug called pemetrexed, given through a lumbar puncture (into the fluid around your brain and spinal cord), for small cell lung cancer that has spread to the brain or its lining and hasn't responded to whole-brain radiation. The goal is to see if it can shrink these tumors and help you feel better.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.